In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
BUSINESS
Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
Chugai Pharmaceutical has decided to postpone the NHI price listing of its breast cancer agent Kadcyla (recombinant trastuzumab emtansine), originally scheduled for later this month, the company said on November 13. “We could not come to terms with the authority…
To read the full story
BUSINESS
- Axcelead DDP, Lilly Ink Research Collaboration Pact
September 6, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Keytruda Nabs Best-Seller Drug Title for 11th Straight Month: Encise
September 6, 2024
- Organon’s OG-8276A for Dysmenorrhea Hits Goal in Japan PIII Study
September 5, 2024
- Daiichi Sankyo Wins Japan Approval for Updated COVID Jab for JN.1
September 5, 2024
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…